Plasma Derived Medicine Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Plasma-derived medicines are biological therapeutics fractionated from donated human plasma, serving as life-saving treatments for patients with immune, hematological, and neurological disorders. The global market reached an estimated $48.0 billion in 2025 and is projected to grow at 9.8% annually, reflecting sustained demand and expanding clinical applications.

• •Immunoglobulin (IVIG/SCIG) products represent the largest segment, used for primary immunodeficiencies, autoimmune neurology, and hematology
• •Albumin and coagulation factors (Factor VIII, IX) constitute significant sub-markets within the overall category
• •Market growth is supported by aging populations, increasing diagnoses of rare diseases, and improved access in emerging economies

Rising prevalence of primary and secondary immunodeficiencies, coupled with expanding label indications for immunoglobulin therapies in neurology and rheumatology, is a primary engine of market expansion. Advances in plasma collection technologies and increased donation rates, particularly in the United States which supplies a substantial portion of global plasma, support growing manufacturing capacity.

• •Growing off-label and approved use of IVIG for neurological conditions such as chronic inflammatory demyelinating polyneuropathy and myasthenia gravis
• •Increased demand for subcutaneous immunoglobulin formulations offering greater patient convenience and reduced healthcare facility burden
• •Expansion of plasma collection centers and higher compensated donor models, especially in the U.S. and Europe

North America dominates the market, driven by high healthcare spending, widespread insurance coverage for biologic therapies, and a robust plasma donation infrastructure, particularly in the United States. Europe follows, with Germany, France, and the UK representing major markets, while the Asia-Pacific region is emerging as the fastest-growing area due to rising healthcare access and increasing awareness of plasma therapies.

• •Immunoglobulins account for roughly 60% of the plasma-derived medicines market, with albumin and coagulation factors comprising the remainder
• •The U.S. represents the largest single-country market and the primary global supplier of source plasma for fractionation
• •Asia-Pacific growth is accelerating as local manufacturers expand capacity and regulatory frameworks evolve to support biologic access

What are the recent trends and outlook?

The market is moving toward more patient-centric delivery formats, with subcutaneous and hybrid formulations gaining share over traditional intravenous products. Ongoing pipeline development in recombinant and gene-therapy alternatives may eventually address some indications currently reliant on plasma-derived products, though plasma collection volumes are expected to remain central to supply for the foreseeable future.

• •Subcutaneous immunoglobulin and longer-acting formulations are reshaping competitive dynamics and patient adherence profiles
• •Manufacturers are pursuing process intensification and continuous fractionation technologies to improve yield and reduce cost
• •Regulatory emphasis on plasma donor safety, pathogen reduction, and supply chain resilience continues to shape industry standards